Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BIC-PHI: Bictegravir/FTC/TAF for the treatment of primary HIV infection
2020-000601-89Phase 2Completed
- Sponsor
- Fundació Clínic per a la Recerca Biomèdica
- Start
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bictegravir + emtricitabine + tenofovir alafenamide in human immunodeficiency virus infection (HIV), sponsored by Fundació Clínic per a la Recerca Biomèdica. Primary endpoint: Virological suppression at 48 weeks (primary). Started Feb 2021; status: completed.
02
Drugs
bictegravir + emtricitabine + tenofovir alafenamide
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2020-000601-89.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000601-89.